| Monogram Health Professional Services Pc | |
|
5410 Maryland Way Ste 301 Brentwood TN 37027-5064 | |
| (615) 673-4455 | |
| Not Available |
| Full Name | Monogram Health Professional Services Pc |
|---|---|
| Speciality | Internal Medicine |
| Location | 5410 Maryland Way Ste 301, Brentwood, Tennessee |
| Authorized Official Name and Position | Shawn Verner (GENERAL COUNSEL AND SECRETARY) |
| Authorized Official Contact | 6159941889 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Monogram Health Professional Services Pc 5410 Maryland Way Ste 301 Brentwood TN 37027-5064 Ph: (615) 673-4455 | Monogram Health Professional Services Pc 5410 Maryland Way Ste 301 Brentwood TN 37027-5064 Ph: (615) 673-4455 |
| NPI Number | 1326655986 |
|---|---|
| Provider Enumeration Date | 09/28/2020 |
| Last Update Date | 11/17/2022 |
| Medicare PECOS PAC ID | 4880004183 |
|---|---|
| Medicare Enrollment ID | O20210111001028 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326655986 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | (* (Not Available)) | Secondary |
| 207RN0300X | Internal Medicine - Nephrology | (* (Not Available)) | Primary |
| Provider Name | Joel Kavanagh |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1740391390 PECOS PAC ID: 7315098530 Enrollment ID: I20090630000188 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Donna R Watson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285866640 PECOS PAC ID: 5092846295 Enrollment ID: I20100702000434 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Nancy Jordan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659400885 PECOS PAC ID: 9537260351 Enrollment ID: I20101112000454 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Justin A Qualls |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1669784930 PECOS PAC ID: 7113167107 Enrollment ID: I20130716000569 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Jacob R Whelan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1023338183 PECOS PAC ID: 0244468544 Enrollment ID: I20140113001459 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Lisa H Terrell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1225447923 PECOS PAC ID: 4486978939 Enrollment ID: I20150112000437 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Hannah Poyner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295239218 PECOS PAC ID: 9032472535 Enrollment ID: I20180416001612 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Tammarin S Collins |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1184129306 PECOS PAC ID: 8820342280 Enrollment ID: I20181121001571 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Lakeshia Arrington |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588121461 PECOS PAC ID: 4385987247 Enrollment ID: I20190515003175 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Judith Stallings |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902235583 PECOS PAC ID: 5698902138 Enrollment ID: I20200115001798 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Shaminder Gupta |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1730183401 PECOS PAC ID: 1658322300 Enrollment ID: I20210122000023 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Dantwan Shawntel Smith |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1659866895 PECOS PAC ID: 8729486477 Enrollment ID: I20220107000808 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Carrie Rebecca Hyde |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1114260726 PECOS PAC ID: 1658696307 Enrollment ID: I20220322000788 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Letoya Franklin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1679930937 PECOS PAC ID: 5496050072 Enrollment ID: I20220519002516 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Venkatasubramanian Srinivasan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1841273729 PECOS PAC ID: 8820078454 Enrollment ID: I20220624002690 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Samantha Yearwood |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1932850427 PECOS PAC ID: 4284000852 Enrollment ID: I20221116003135 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Jaclyn Masulli |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124565171 PECOS PAC ID: 5294149761 Enrollment ID: I20221207000575 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Susan Bell |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1336285873 PECOS PAC ID: 7517122013 Enrollment ID: I20230130002201 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Zahily Fals |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1598078115 PECOS PAC ID: 6103121520 Enrollment ID: I20230823004197 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Amanda Bahler |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245785013 PECOS PAC ID: 2860776481 Enrollment ID: I20231121002201 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Rick Michel |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1396079562 PECOS PAC ID: 3375938673 Enrollment ID: I20231204001368 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Katherine Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1205101110 PECOS PAC ID: 1254594955 Enrollment ID: I20231206001487 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Jaydra Woods |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114319977 PECOS PAC ID: 5890014633 Enrollment ID: I20231206001923 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Lacey Lane Blessitt |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1972864148 PECOS PAC ID: 6800247909 Enrollment ID: I20240112000691 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
| Provider Name | Cambridge Odeasie Hendrix |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881376606 PECOS PAC ID: 8820440316 Enrollment ID: I20240119003711 |
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
News Archive
The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.
A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.
Modern medicine may have stopped short of blood-letting, leeches and purges but parasitic worms could be making a come-back!
The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."
Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.
› Verified 2 days ago
Bill G. Sekulovski, Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 104 Eastpark Dr, Suite 102, Brentwood, TN 37027 Phone: 615-373-5700 | |
Monogram Health Professional Services Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5410 Maryland Way Ste 301, Brentwood, TN 37027 Phone: 615-673-4455 | |
Hospitalist Medicine Physicians Of Florida - Palm Coast, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 5410 Maryland Way Ste 300, Brentwood, TN 37027 Phone: 615-377-5658 | |
Vanguard Crewcare Wellness Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5500 Maryland Way Ste 200, Brentwood, TN 37027 Phone: 615-577-4927 | |
Bluesky Housecalls, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 109 Westpark Dr, Brentwood, TN 37027 Phone: 615-340-6840 Fax: 615-600-4804 | |
Brentwood Family Care Center, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 5046 Thoroughbred Ln, Brentwood, TN 37027 Phone: 615-370-8080 Fax: 615-371-8906 | |
Elite Physicians Group Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 9005 Overlook Blvd, Brentwood, TN 37027 Phone: 615-873-2975 Fax: 615-873-2975 |